Literature DB >> 19495975

Aquaporin-2 urinary excretion in cirrhosis: relationship to vasopressin and nitric oxide.

Sook Hee Chung1, Dae Won Jun, Kyung Tae Kim, Jeong Don Chae, Eun Kyoung Park, Byoung Kwan Son, Seong Hwan Kim, Yun Ju Jo, Young Sook Park.   

Abstract

The aquaporin (AQP) water channel plays an important role in the regulation of water. AQP2 is expressed in the collection duct of the kidney, serving as the final channel that helps to regulate water excretion in the kidneys and affecting the regulation of water and hyponatremia in cirrhotic patients. So far, research on aquaporin expression in cirrhosis has had various results. The purpose of this study is to investigate the factors that affect the regulation of expression of AQP in patients with cirrhosis. The study comprised 81 cirrhosis patients and 18 control subjects. In each group, 24-h urine was collected and nitric oxide and vasopressin levels were measured in the blood. The amount of urinary AQP was measured by Western blot. In this study, the positivity rate and amount of expression of AQP was higher in the cirrhotic group than that of the control group. AQP expression in urine was also compared between the groups with use of diuretics and the groups with no use of diuretics. A 57.4% positivity was observed with the former, whereas a 51.5% was seen in the latter. No significance was found between the groups (P = 0.581). Expression of AQP in compensated cirrhotic patients is significantly higher than decompensated cirrhotic patients and is especially higher in cirrhotic patients with ascites than with no ascites. There is no relationship between the concentration of vasopressin and expression of AQP. Concentration of serum NOx is higher in cirrhotic patients than the control group and there is a positive association between the concentration of serum nitric oxide and AQP in urine. In conclusion, expression of AQP is increased in cirrhotic patients and is significantly higher in patients with ascites. There is a positive association between the expression of AQP and concentration of serum nitric oxide.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19495975     DOI: 10.1007/s10620-009-0829-x

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  20 in total

Review 1.  [Aquaporins and renal water metabolism. Role in the physiopathology of water retention in cirrhosis].

Authors:  P Fernández-Llama
Journal:  Gastroenterol Hepatol       Date:  2001-04       Impact factor: 2.102

2.  Decreased vasopressin-mediated renal water reabsorption in rats with compensated liver cirrhosis.

Authors:  T E Jonassen; S Nielsen; S Christensen; J S Petersen
Journal:  Am J Physiol       Date:  1998-08

3.  Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial.

Authors:  Alexander L Gerbes; Veit Gülberg; Pere Ginès; Guy Decaux; Peter Gross; Hassan Gandjini; Jacques Djian
Journal:  Gastroenterology       Date:  2003-04       Impact factor: 22.682

4.  The role of nitric oxide in the pathogenesis of systemic and splanchnic vasodilation in cirrhotic rats before and after the onset of ascites.

Authors:  Paolo Angeli; Guillermo Fernández-Varo; Virna Dalla Libera; Silvano Fasolato; Alessandra Galioto; Vicente Arroyo; Antonietta Sticca; Silvia Guarda; Angelo Gatta; Wladimiro Jiménez
Journal:  Liver Int       Date:  2005-04       Impact factor: 5.828

5.  Aquaporin-1 and aquaporin-2 urinary excretion in cirrhosis: Relationship with ascites and hepatorenal syndrome.

Authors:  Christina Esteva-Font; Maria E Baccaro; Patricia Fernández-Llama; Laia Sans; Monica Guevara; Elisabet Ars; Wladimiro Jiménez; Vicente Arroyo; Jose A Ballarín; Pere Ginès
Journal:  Hepatology       Date:  2006-12       Impact factor: 17.425

6.  Increased urinary excretion of aquaporin 2 in patients with liver cirrhosis.

Authors:  P Ivarsen; J Frøkiaer; N K Aagaard; E F Hansen; F Bendtsen; S Nielsen; H Vilstrup
Journal:  Gut       Date:  2003-08       Impact factor: 23.059

7.  Pathogenesis of arterial hypotension in cirrhotic rats with ascites: role of endogenous nitric oxide.

Authors:  J Clària; W Jiménez; J Ros; M Asbert; A Castro; V Arroyo; F Rivera; J Rodés
Journal:  Hepatology       Date:  1992-02       Impact factor: 17.425

8.  Role of water channel AQP-CD in water retention in SIADH and cirrhotic rats.

Authors:  N Fujita; S E Ishikawa; S Sasaki; G Fujisawa; K Fushimi; F Marumo; T Saito
Journal:  Am J Physiol       Date:  1995-12

9.  Enhanced endothelium-dependent vasodilation in patients with cirrhosis.

Authors:  A Albillos; I Rossi; G Cacho; M V Martínez; I Millán; L Abreu; C Barrios; P Escartín
Journal:  Am J Physiol       Date:  1995-03

10.  Increased gene expression of water channel in cirrhotic rat kidneys.

Authors:  Y Asahina; N Izumi; N Enomoto; S Sasaki; K Fushimi; F Marumo; C Sato
Journal:  Hepatology       Date:  1995-01       Impact factor: 17.425

View more
  4 in total

1.  Urinary excretion of the water channel aquaporin 2 correlated with the pharmacological effect of tolvaptan in cirrhotic patients with ascites.

Authors:  Hiroyuki Nakanishi; Masayuki Kurosaki; Takanori Hosokawa; Yuka Takahashi; Jun Itakura; Shoko Suzuki; Yutaka Yasui; Nobuharu Tamaki; Natsuko Nakakuki; Hitomi Takada; Mayu Higuchi; Yasuyuki Komiyama; Tsubasa Yoshida; Kenta Takaura; Tsuguru Hayashi; Konomi Kuwabara; Sei Sasaki; Namiki Izumi
Journal:  J Gastroenterol       Date:  2015-11-26       Impact factor: 7.527

2.  Vasopressin V2-receptor antagonists in patients with cirrhosis, ascites and hyponatremia.

Authors:  Shahid Habib; Thomas D Boyer
Journal:  Therap Adv Gastroenterol       Date:  2012-05       Impact factor: 4.409

Review 3.  Do vasopressin V2 receptor antagonists benefit cirrhotics with refractory ascites?

Authors:  Hiroshi Fukui
Journal:  World J Gastroenterol       Date:  2015-11-07       Impact factor: 5.742

Review 4.  The Trafficking of the Water Channel Aquaporin-2 in Renal Principal Cells-a Potential Target for Pharmacological Intervention in Cardiovascular Diseases.

Authors:  Tanja Vukićević; Maike Schulz; Dörte Faust; Enno Klussmann
Journal:  Front Pharmacol       Date:  2016-02-11       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.